# LLY stock has increased 28.2% over this time frame, while the broader S&P 500 Index ($SPX) has gained 30.6%.

*biotech · news · 2026-05-06 · Barchart*

## Key points

- Eli Lilly raised its 2026 revenue guidance to $82–$85 billion and adjusted EPS to $35.50–$37.
- Q1 2026 revenue grew 56% year-over-year, driven by Mounjaro and Zepbound generating $12.8 billion in sales.
- Newly launched Foundayo (orforglipron) already has over 20,000 patients and 8,000 prescribers.
- Consensus analyst rating is 'Strong Buy,' with a mean price target reflecting 23.9% upside.
- Barclays recently raised Eli Lilly's price target to $1,400, maintaining an 'Overweight' rating.

**Companies:** Eli Lilly and Company
**Countries:** United States, China, Japan

[Read the full story on Barchart](https://www.barchart.com/story/news/1745234/do-wall-street-analysts-like-eli-lilly-stock)

---

Canonical: https://newsio.io/n/594c7b38-1f34-4833-8af3-f0f90e4bcb9d/lly-stock-has-increased-28-2-over-this-time-frame-while-the-broader-sp-500-index
Summarized by Newsio from Barchart. https://newsio.io/how-it-works